ClinicalTrials.gg
RecruitingNCT06825013SOUNDUpdated Feb 13, 2025

Bronchodilators and Lung Mechanics During Exercise in COPD

A Phase 4 interventional study of Bronchodilators inhalation and Placebo in COPD, sponsored by Dr. J. Alberto Neder. Recruiting at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Dr. J. Alberto Neder · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada — 40 open to participants now, 49 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Canada.

Planned enrollment
274th of 340
25 · median 207
Started
2024
with 11 others
Phase 4
42 of 398
4 open now
Primary completion
2027-01
later than 20 of 48 live
Registered
378th of 398
by date

Among the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, this one is the 274th largest by planned enrollment of the 340 interventional ones that give a count, is one of 12 that started in 2024, is one of 42 in phase 4, reaches primary completion later than 20 of the 48 other live ones, and was the 378th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

40 of the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, or all of them as a file.
02

Study summary

Bronchodilators are medications that open the bronchi to help patients with COPD to breathe better. It is still not known exactly how this effect improves shortness of breath in people with COPD. The goal of this clinical trial is to determine whether bronchodilators lower resistance in the smallest airways in the lungs, and whether this will improve the feeling of breathlessness in these patients.

The main questions the investigators attempt to answer are:

  • In patients with COPD, does treatment with a short-acting bronchodilator improve small airway resistance during exercise?
  • In patients with COPD, does acute treatment with short-acting bronchodilator improve breathlessness and exercise endurance?

The investigators will compare short-acting bronchodilators to placebo (a substance that contains no drug) to see if the bronchodilator medications improve small airway resistance and breathlessness during exercise.

Participants will:

  • Visit the research laboratory 3 visits to complete tests of lung function and exercise
  • Complete 2 identical visits (Visit 2 and 3), one in which the participant receives bronchodilator and one in which the participant receives placebo.
Read the detailed description

Small airways disease is a major cause of increased airway resistance and obstruction in chronic obstructive pulmonary disease (COPD). Small airways are those airways beyond generation 8 that are \<2 mm in diameter. Due to lung geometry and the mechanism of particle deposition, treatment of small airway disease is challenging and a major clinical concern. Recent advances in respiratory medication delivery devices have purported to improve delivery of medication to the small airways, thus providing better physiologic and symptomatic relief. One such example is Breztri™ Aerosphere©, is a pressurized metered-dose inhaler (pMDI) that delivers triple therapy (long-acting beta-2 agonist, long-acting muscarinic antagonist, and an inhaled corticosteroid), and is currently approved in Canada for patients with COPD. Preliminary evidence has suggested that this product reduced mortality risk and had beneficial effects on exertional dyspnea (shortness of breath), notably in symptomatic patients who have been treated with dry powder inhalers (DPIs). Modeling studies have shown better deposition of drug into the small airways with the pMDI than the DPI; however, it remains unclear whether improved deposition is sufficient to improve small airways function in patients with COPD, and whether these changes result in commensurate improvement in dyspnea and exercise tolerance. Uncovering the mechanisms of dyspnea improvement is a crucial step to provide evidence-based rationale for using pMDI to mitigate the burden of this key patient reported outcome.

Dyspnea during exercise (exertion) in COPD arises when the drive to breathe (neural) is not properly rewarded by the output of the lungs (respiratory mechanics), a phenomenon called "neuromechanical dissociation". In patients with moderate-to-severe COPD, this 'neuromechanical dissociation' is largely a result of impairment in the function of the small airways (airways that are \<2mm in diameter) which conspire to induce pulmonary gas trapping and, consequently, increase lung volumes ("hyperinflation"). During exercise when ventilatory demands increase, the reduced time constant for lung emptying (i.e., impaired expiratory time due to increased breathing frequency) leads to acute-on-chronic lung hyperinflation which accelerates attainment of critical inspiratory constraints (i.e., tidal volume expansion is limited), and thus, patients have significantly greater dyspnea and earlier exercise termination. It is reasonable to assume that any inhaled medication for COPD with enhanced access to the small airways could reduce or delay dynamic hyperinflation during exercise and improve a patient's shortness of breath.

MAIN RESEARCH QUESTION In patients with COPD and significant resting lung hyperinflation, does acute treatment with a short-acting bronchodilator (salbutamol sulfate + ipratropium bromide) improve impulse oscillometry derived small airway resistance during cardiopulmonary exercise compared to placebo.

SECONDARY RESEARCH QUESTIONS In patients with COPD and significant resting lung hyperinflation, does acute treatment with short-acting bronchodilator (salbutamol sulfate + ipratropium bromide) improve exertional dyspnea and exercise tolerance during cardiopulmonary exercise compared to placebo. Are improvements in small airway resistance, associated with a reduction in inspiratory neural drive and improved lung mechanics, as measured by diaphragm electromyography (EMGdi).

RESEARCH METHODS Study design: This is a single center, investigator-initiated, prospective, cross over study being conducted over 2-3 weeks.

Study outline:

After giving written informed consent, all participants will be asked to complete 3 visits to the Respiratory Investigation Unit, Kingston General Hospital. Each visit will be conducted at the same time, in the morning, 2 to 7 days apart.

Visit 1 (eligibility assessment): Detailed medical history, physical examination and ECG will be performed. Participants will perform complete pulmonary function testing including spirometry, plethysmography, diffusing capacity for carbon monoxide (DLCO), small airway function assessment (impulse oscillometry (IOS), single-breath and multiple-breath nitrogen washout tests). Participants will complete a symptom-limited incremental cardiopulmonary exercise test (CPET) to determine maximum exercise capacity. PFT and CPET procedures will be conducted according to consensus recommendations.

Visit 2/3 (Constant Work Rate Cardiopulmonary Exercise Test with Placebo or Bronchodilator): Spirometry, body plethysmography, impulse oscillometery, and static and dynamic lung compliance measurements will be performed pre-intervention and 15 minutes post intervention (either dual short-acting bronchodilator (salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg) or a placebo (normal saline)). Participants will then perform a constant work rate tests at 75% peak exercise capacity (determined at V1). Participant will perform exercise on a stationary bicycle while breathing through a mouthpiece with nose clips on, which allows for the breath-by-breath recording of ventilatory and metabolic variables throughout exercise. After approximately 6 minutes of relaxed, baseline breathing, participants will be asked to pedal for 1 minute against no resistance to warm up. The load will then increase to constant work rate (determined at V1), participants will continue to pedal until symptom limitation. Every 2 minutes during exercise, the participant will perform an impulse oscillometery test for assessment of small airways function, followed by an inspiratory capacity maneuver to determine lung volumes. Respiratory discomfort (dyspnea) and leg fatigue will be assessed using the modified Borg 0-10 scale. Vital signs (BP, HR, SpO2) will be monitored throughout each exercise test and during recovery.

Diaphragm EMG and Respiratory Pressure Measurements: At the beginning of Visit 2 and 3, the investigators will apply a topical anesthetic spray to the nasal passages and throat of the participant. A thin catheter (diameter 2 mm) will be inserted by the investigator through the nose down the throat and into the esophagus and top part of stomach. This catheter measures the electric activity (EMG) of the diaphragm, which provides a surrogate measurement of the inspiratory neural drive to breathe. It also measures pressures in the esophagus within the chest as well as in the stomach, which gives useful information about the work of breathing and breathing mechanics.

03

Conditions studied

  • COPD

Keywords

  • Bronchodilators
  • Dyspnea
  • COPD
  • Exercise
  • Lung mechanics
  • Physiology
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of
  • Male or female ≥40-years-of-age
  • Current or former smokers with ≥20 pack-year history
  • (FEV1)/ forced vital capacity (FVC)\<lower limit of normal
  • Pre-Post Change of FVC ≥ 10% predicted after 400 mcg inhaled salbutamol
  • Functional residual capacity ≥120%predicted and/or the
  • Modified Medical Research Council dyspnea scale ≥ 2
  • Clinically stable as defined by no exacerbations in the preceding 6 weeks
  • Ability to provide and perform all study procedures

Exclusion criteria

Exclusion Criteria:

  • Major cardiopulmonary diseases other than (asthma, interstitial lung disease, pulmonary hypertension, and congestive heart failure)
  • Neuromuscular or musculoskeletal disease
  • Use of daytime oxygen or exercise induced O2 desaturation to \< 80% on room air;
  • Any other disorder that may contribute to exertional dyspnoea and/or exercise intolerance
  • Any to cardiopulmonary exercise testing
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Bronchodilator

    Participants will receive a combination short-acting bronchodilator (Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)) via nebulizer.

    Drug: Bronchodilators inhalation

  • Placebo comparator
    Placebo

    Participants will receive normal saline via nebulizer.

    Drug: Placebo

Interventions

  • DrugBronchodilators inhalation

    Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)

  • DrugPlacebo

    Nebulized saline

06

What researchers measure

Primary outcomes

  1. Airway resistance

    Primary objective is to measure airway resistance measured by impulse oscillometry at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

Secondary outcomes

  1. Inspiratory neural drive

    Secondary objective is to measure inspiratory neural drive (IND) by diaphragm activation (EMGdi%max) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

  2. Esophageal Pressure (Pes)

    Secondary objective is to measure esophageal pressure (Pes) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

  3. Gastric Pressure (Pga)

    Secondary objective is to measure gastric pressure (Pga) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

  4. Trans-diaphragmatic Pressure (Pdi)

    Secondary objective is to measure trans-diaphragmatic pressure (Pdi) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

  5. Operating lung volumes

    Secondary objective is to measure inspiratory capacity at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

  6. Exertional dyspnea

    Primary objective is to measure perceptual (e.g. intensity of dyspnea) responses at isotime (maximum exercise time achieved by all participants) during a standardized cardiopulmonary exercise testing (cycle ergometer).

    Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise

  7. Exercise tolerance

    Exercise tolerance will be assessed as the time from start of loaded pedaling to end of loaded exercise.

    Time frame: Within 10-12 min from start of cardiopulmonary exercise test

07

Study locations

1 of 1 sites recruiting
  • Respiratory Investigation Unit, Kingston Health Sciences Center
    Kingston, Ontario K7L 2V6, Canada
    Recruiting
    • J Alberto Neder Serafini, MD, Phd · Contactnederalb@gmail.com · 800-549-6666
    • J Alberto Neder Serafini, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Data will not be shared until completion of the trial and final analysis. Anonymized data may be made available upon reasonable request after appropriate ethical approval and institutional data sharing agreements

Supporting information: Study protocol

Time frame: Data will not be released until study completion (anticipated January 2027).

Access criteria: Data will be released on reasonable request after appropriate ethical approval, anonymization, and data sharing agreements to ensure data integrity and participant privacy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 26 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 13, 2025
StartActual
Nov 10, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06825013
Lead sponsor
Dr. J. Alberto Neder
Responsible party
Dr. J. Alberto Neder (Dr. Alberto Neder, Professor, Dept. of Respirology, Queen's University, Queen's University) — Sponsor-investigator
First posted
Feb 13, 2025
Start date
Nov 10, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 13, 2025

Study contacts

J Alberto Neder Serafini, MD, PhD
Contact
nederalb@gmail.com
800-985-8891
J Alberto Neder, MD, PhD
principal investigator · Queen's University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion